Early tumor regrowth is a contributor to impaired survival in patients with completely resected advanced ovarian cancer. An exploratory analysis of the Intergroup trial AGO-OVAR 12

There is no fulltext present in this item.

Title:	Early tumor regrowth is a contributor to impaired survival in patients with completely resected advanced ovarian cancer. An exploratory analysis of the Intergroup trial AGO-OVAR 12
Author(s):	Heitz, F.; Harter, P.; Avail-Lundqvist, E.; Reuss, A.; Pautier, P.; Cormio, G.; Ottevanger, N. ; Merger, M.; Bois, A. du
Publication year:	2019
Source:	Gynecologic Oncology, vol. 152, iss. 2, (2019), pp. 235-242
ISSN:	0090-8258
DOI:	https://doi.org/10.1016/j.ygyno.2018.11.008
Publication type:	Article / Letter to editor
Please use this identifier to cite or link to this item : http://hdl.handle.net/2066/201794
Display more details
Subject:	All institutes and research themes of the Radboud University Medical Center Radboudumc 17: Women's cancers RIHS: Radboud Institute for Health Sciences
Organization:	Medical Oncology IQ Healthcare
Journal title:	Gynecologic Oncology
Volume:	vol. 152
Issue:	iss. 2
Page start:	p. 235
Page end:	p. 242